Aim. – The best way to treat pregnant patients who have type 1 diabetes is still unclear. For this reason, the present study compared metabolic control and maternal–fetal outcomes in patients treated with continuous subcutaneous infusions of rapid-acting insulin analogues (CSII) or with insulin glargine and multiple daily injections of rapid-acting insulin analogues (glargine–MDI). Methods. – This retrospective multicentre study involved 144 women with type 1 diabetes, 100 of whom were using CSII and 44 glargine–MDI. Outcomes analyzed were metabolic control, diabetes complications, pregnancy outcome, perinatal morbidity and mortality, and fetal malformations. Results. – The two groups were comparable for age, prepregnancy BMI, primiparous rate and diabetes complications, although patients using CSII had longer duration of diabetes (P = 0.03) and higher White classifications (P = 0.04). In both groups, metabolic control improved during pregnancy, but good control was reached earlier among patients using CSII. At parturition, patients using CSII had lower HbA1c (6.2 ± 0.7% vs 6.5 ± 0.8%; P = 0.02) and required less insulin (P < 0.01). Weight gain was similar in both groups, and maternal–fetal outcomes did not differ. Conclusion. – In pregnant patients with type 1 diabetes, MDI and CSII are equivalent in terms of metabolic control and fetal–maternal outcomes, although patients using CSII achieved good control earlier and with less insulin.

Type 1 diabetes control and pregnancy outcomes in women treated with continuous subcutaneous insulin infusion (CSII) or with insulin glargine and multiple daily injections of rapid-acting insulin analogues (glargine-MDI).

DI BENEDETTO, Antonino;
2011

Abstract

Aim. – The best way to treat pregnant patients who have type 1 diabetes is still unclear. For this reason, the present study compared metabolic control and maternal–fetal outcomes in patients treated with continuous subcutaneous infusions of rapid-acting insulin analogues (CSII) or with insulin glargine and multiple daily injections of rapid-acting insulin analogues (glargine–MDI). Methods. – This retrospective multicentre study involved 144 women with type 1 diabetes, 100 of whom were using CSII and 44 glargine–MDI. Outcomes analyzed were metabolic control, diabetes complications, pregnancy outcome, perinatal morbidity and mortality, and fetal malformations. Results. – The two groups were comparable for age, prepregnancy BMI, primiparous rate and diabetes complications, although patients using CSII had longer duration of diabetes (P = 0.03) and higher White classifications (P = 0.04). In both groups, metabolic control improved during pregnancy, but good control was reached earlier among patients using CSII. At parturition, patients using CSII had lower HbA1c (6.2 ± 0.7% vs 6.5 ± 0.8%; P = 0.02) and required less insulin (P < 0.01). Weight gain was similar in both groups, and maternal–fetal outcomes did not differ. Conclusion. – In pregnant patients with type 1 diabetes, MDI and CSII are equivalent in terms of metabolic control and fetal–maternal outcomes, although patients using CSII achieved good control earlier and with less insulin.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11570/1912941
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 47
  • ???jsp.display-item.citation.isi??? 41
social impact